Gossamer Bio, Inc.
GOSS$271M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSAN DIEGO144 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
GOSS News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
GB001
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
GB002 (seralutinib)
Pulmonary Artery Hypertension
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GB001 | Phase 2 | Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) | - | - |
GB002 (seralutinib) | Phase 2 | Pulmonary Artery Hypertension | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply